Clincosm LogoSign in Get a demo

sintilimab

Showing 1 - 12 of 12
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

Sintilimab in Combination With Chemoradiotherapy in High-risk

Recruiting
  • Nasopharyngeal Carcinoma
  • Sintilimab
  • Sintilimab (PD-1 Antibody)
  • Nanning, Guangxi, China
    Guangxi Medical University Cancer Hospital
Jan 29, 2023

Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage, Anlotinib Trial in Guangzhou (Sintilimab)

Completed
  • Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
  • +7 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 6, 2022

HER2-positive, Locally Advanced Solid Tumor, Immunotherapy Trial in Beijing (sintilimab, Trastuzumab, S-1 plus oxaliplatin)

Not yet recruiting
  • HER2-positive
  • +6 more
  • Beijing, China
    Cancer Hospital & Institute, Chinese Academy of Medical Sciences
Mar 28, 2022

Uterine Cervical Tumors, Sintilimab Trial in Xuzhou (Sintilimab, Cisplatin, External Beam Radiotherapy (EBRT))

Recruiting
  • Uterine Cervical Neoplasms
  • Sintilimab
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Dec 24, 2021

Gastric Cancer, Perioperative, Sintilimab Trial in Tianjin (Sintilimab, S-1, Oxaliplatin)

Recruiting
  • Gastric Cancer
  • +2 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Aug 25, 2021

Colorectal Cancer, Immunotherapy, Anlotinib Trial in Shanghai (Anlotinib plus Sintilimab)

Recruiting
  • Colorectal Cancer
  • +5 more
  • Anlotinib plus Sintilimab
  • Shanghai, China
    Department of Medical Oncology, Shanghai Changzheng Hospital
Dec 28, 2020

Carcinoma, Hepatocellular, Liver Tumors, Sintilimab Trial in Guangzhou (Hepatic arterial infusion chemo, Lenvatinib, Sintilimab)

Unknown status
  • Carcinoma, Hepatocellular
  • +3 more
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Second Affiliated Hospital of Guangzhou Medical University
Dec 20, 2020

Renal Cell Carcinoma, FH-deficient, Sintilimab Trial (Sintilimab)

Not yet recruiting
  • Renal Cell Carcinoma
  • +2 more
  • (no location specified)
May 9, 2020

Brain Metastases, Non Small Cell Lung Cancer, Sintilimab Trial in Guangzhou (sintilimab)

Unknown status
  • Brain Metastases
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University of Cancer Center
Dec 25, 2019

DLBCL, Sintilimab, TP53 Mutation Trial (Sintilimab-R-CHOP)

Unknown status
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • (no location specified)
Dec 9, 2019

NSCLC Stage IV, Brain Metastases, SRS Trial in Wuhan (SRS sequential sintilimab)

Unknown status
  • NSCLC Stage IV
  • +3 more
  • SRS sequential sintilimab
  • Wuhan, Hubei, China
    Union hospital
Nov 26, 2019